MDNA Stock Overview
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medicenna Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.92 |
| 52 Week High | CA$2.10 |
| 52 Week Low | CA$0.21 |
| Beta | 1.33 |
| 1 Month Change | 28.00% |
| 3 Month Change | 326.67% |
| 1 Year Change | 102.11% |
| 3 Year Change | -59.06% |
| 5 Year Change | 170.42% |
| Change since IPO | -28.89% |
Recent News & Updates
Recent updates
We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully
Oct 18
Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth
Feb 28Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation
Nov 08Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?
Mar 01We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely
Aug 07Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?
Apr 14We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely
Dec 30
Shareholder Returns
| MDNA | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 11.0% | -2.5% | 1.2% |
| 1Y | 102.1% | -37.9% | 6.1% |
Return vs Industry: MDNA exceeded the Canadian Biotechs industry which returned -37.9% over the past year.
Return vs Market: MDNA exceeded the Canadian Market which returned 6.1% over the past year.
Price Volatility
| MDNA volatility | |
|---|---|
| MDNA Average Weekly Movement | 21.8% |
| Biotechs Industry Average Movement | 13.6% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: MDNA's share price has been volatile over the past 3 months.
Volatility Over Time: MDNA's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 16 | Fahar Merchant | www.medicenna.com |
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors.
Medicenna Therapeutics Corp. Fundamentals Summary
| MDNA fundamental statistics | |
|---|---|
| Market cap | CA$107.94m |
| Earnings (TTM) | -CA$15.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.7x
P/E RatioIs MDNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDNA income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$15.42m |
| Earnings | -CA$15.42m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MDNA perform over the long term?
See historical performance and comparison